NASDAQ:INCY Incyte (INCY) Stock Forecast, Price & News $62.37 -0.17 (-0.27%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$62.18▼$62.9050-Day Range$61.51▼$75.5152-Week Range$60.71▼$86.29Volume1.38 million shsAverage Volume1.71 million shsMarket Capitalization$13.91 billionP/E Ratio43.01Dividend YieldN/APrice Target$81.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Incyte MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside30.4% Upside$81.50 Price TargetShort InterestHealthy3.19% of Float Sold ShortDividend StrengthN/ASustainability-2.42Upright™ Environmental ScoreNews Sentiment1.04Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth40.14%From $2.89 to $4.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.16 out of 5 starsMedical Sector13th out of 985 stocksCommercial Physical Research Industry2nd out of 16 stocks 4.1 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 5 buy ratings, 9 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.50, Incyte has a forecasted upside of 30.4% from its current price of $62.50.Amount of Analyst CoverageIncyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.19% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Incyte has recently decreased by 5.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 3.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 29.94% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Janus-associated kinase (JAK) inhibitors", "Ponatinib", and "Tafasitamab" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -2.42. Previous Next 3.4 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Incyte this week, compared to 7 articles on an average week.Search Interest22 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat Follows9 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have not sold or bought any company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 40.14% in the coming year, from $2.89 to $4.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 43.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 43.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.46.Price to Earnings Growth RatioIncyte has a PEG Ratio of 3.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Incyte (NASDAQ:INCY) StockIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.Read More Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Stock News HeadlinesMay 29, 2023 | finance.yahoo.comShareholders in Incyte (NASDAQ:INCY) are in the red if they invested three years agoMay 27, 2023 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) Receives $81.73 Consensus Price Target from AnalystsJune 5, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 25, 2023 | finance.yahoo.comData from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid CongressMay 17, 2023 | morningstar.comIncyte Corp INCY Stock QuoteMay 16, 2023 | nasdaq.comGuru Fundamental Report for INCYMay 16, 2023 | seekingalpha.comIncyte Corporation 2023 Q1 - Results - Earnings Call PresentationMay 10, 2023 | marketwatch.comIncyte Corp. stock falls Tuesday, underperforms marketJune 5, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 10, 2023 | bizjournals.comIncyte expands leadership team to maximize narrowed product pipelineMay 10, 2023 | marketwatch.comIncyte Corp. stock falls Wednesday, underperforms marketMay 9, 2023 | marketwatch.comIncyte Corp. stock underperforms Monday when compared to competitorsMay 8, 2023 | finance.yahoo.comIncyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership RoleMay 7, 2023 | marketwatch.comIncyte Corp. stock rises Friday, still underperforms marketMay 7, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Incyte Co. Raised by Analyst (NASDAQ:INCY)May 6, 2023 | americanbankingnews.comJMP Securities Lowers Incyte (NASDAQ:INCY) Price Target to $93.00May 6, 2023 | americanbankingnews.comBMO Capital Markets Cuts Incyte (NASDAQ:INCY) Price Target to $70.00May 5, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) PT Lowered to $70.00May 5, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) Price Target Cut to $82.00May 5, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) PT Lowered to $73.00May 5, 2023 | americanbankingnews.comStockNews.com Downgrades Incyte (NASDAQ:INCY) to BuyMay 5, 2023 | americanbankingnews.comQ1 2023 Earnings Estimate for Incyte Co. (NASDAQ:INCY) Issued By OppenheimerMay 4, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) Price Target Lowered to $93.00 at JMP SecuritiesMay 4, 2023 | americanbankingnews.comBank of America Lowers Incyte (NASDAQ:INCY) to NeutralMay 4, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) Shares Gap Down to $75.34May 4, 2023 | americanbankingnews.comIncyte (NASDAQ:INCY) Given New $70.00 Price Target at Royal Bank of CanadaMay 4, 2023 | americanbankingnews.comVNET Group Reiterates "Maintains" Rating for Incyte (NASDAQ:INCY)See More Headlines INCY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCY Company Calendar Last Earnings2/07/2023Today6/05/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,324Year Founded1991Price Target and Rating Average Stock Price Forecast$81.50 High Stock Price Forecast$100.00 Low Stock Price Forecast$61.00 Forecasted Upside/Downside+30.3%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$1.45 Trailing P/E Ratio43.13 Forward P/E Ratio21.64 P/E Growth3.1Net Income$340.66 million Net Margins9.35% Pretax Margin14.71% Return on Equity9.99% Return on Assets7.62% Debt Debt-to-Equity Ratio0.01 Current Ratio3.95 Quick Ratio3.91 Sales & Book Value Annual Sales$3.39 billion Price / Sales4.11 Cash Flow$2.43 per share Price / Cash Flow25.69 Book Value$19.64 per share Price / Book3.18Miscellaneous Outstanding Shares223,090,000Free Float184,048,000Market Cap$13.95 billion OptionableOptionable Beta0.72 Social Links Key ExecutivesHerve HoppenotChairman, President & Chief Executive OfficerChristiana StamoulisChief Financial Officer & Executive Vice PresidentSteven H. SteinChief Medical Officer & Executive Vice PresidentDashyant DhanakChief Scientific Officer & Executive VPBarry P FlannellyEVP & General Manager-North AmericaKey CompetitorsICON PublicNASDAQ:ICLRCharles River Laboratories InternationalNYSE:CRLMedpaceNASDAQ:MEDPSyneos HealthNASDAQ:SYNHAvantorNYSE:AVTRView All CompetitorsInsiders & InstitutionsOntario Teachers Pension Plan BoardBought 37,482 shares on 6/1/2023Ownership: 0.023%Searle & CO.Sold 200 shares on 6/1/2023Ownership: 0.005%ProShare Advisors LLCBought 283 shares on 5/26/2023Ownership: 0.027%Toroso Investments LLCSold 12,503 shares on 5/23/2023Ownership: 0.006%Putnam Investments LLCBought 80,469 shares on 5/22/2023Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions INCY Stock - Frequently Asked Questions Should I buy or sell Incyte stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. View INCY analyst ratings or view top-rated stocks. What is Incyte's stock price forecast for 2023? 15 analysts have issued 1-year target prices for Incyte's stock. Their INCY share price forecasts range from $61.00 to $100.00. On average, they predict the company's share price to reach $81.50 in the next year. This suggests a possible upside of 30.3% from the stock's current price. View analysts price targets for INCY or view top-rated stocks among Wall Street analysts. How have INCY shares performed in 2023? Incyte's stock was trading at $80.32 at the start of the year. Since then, INCY stock has decreased by 22.1% and is now trading at $62.54. View the best growth stocks for 2023 here. Are investors shorting Incyte? Incyte saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 7,010,000 shares, a decrease of 5.9% from the April 30th total of 7,450,000 shares. Based on an average trading volume of 1,590,000 shares, the short-interest ratio is currently 4.4 days. Currently, 3.2% of the shares of the company are sold short. View Incyte's Short Interest. When is Incyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our INCY earnings forecast. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, February, 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.03. The biopharmaceutical company had revenue of $926.70 million for the quarter, compared to analyst estimates of $880.25 million. Incyte had a net margin of 9.35% and a trailing twelve-month return on equity of 9.99%. The business's revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.07) earnings per share. Read the conference call transcript. What ETFs hold Incyte's stock? ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), ARK Genomic Revolution ETF (ARKG), VanEck Biotech ETF (BBH), IQ U.S. Mid Cap R&D Leaders ETF (MRND), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ASYMmetric Smart S&P 500 ETF (ASPY) and OneAscent Large Cap Core ETF (OALC). What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA). What is Incyte's stock symbol? Incyte trades on the NASDAQ under the ticker symbol "INCY." Who are Incyte's major shareholders? Incyte's stock is owned by many different institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (16.22%), BlackRock Inc. (9.25%), Dodge & Cox (8.67%), State Street Corp (4.18%), Renaissance Technologies LLC (2.51%) and Geode Capital Management LLC (1.78%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Incyte's stock price today? One share of INCY stock can currently be purchased for approximately $62.54. How much money does Incyte make? Incyte (NASDAQ:INCY) has a market capitalization of $13.95 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.45 on an earnings per share basis. How many employees does Incyte have? The company employs 2,324 workers across the globe. How can I contact Incyte? Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750. This page (NASDAQ:INCY) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.